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Infectious diseases exert a constant evolutionary pressure on the
genetic makeup of our innate immune system. Polymorphisms in
Toll-like receptor 4 (TLR4) have been related to susceptibility to
Gram-negative infections and septic shock. Herewe show that two
polymorphisms of TLR4, Asp299Gly and Thr399Ile, have unique
distributions in populations from Africa, Asia, and Europe. Genetic
and functional studies are compatible with a model in which the
nonsynonymous polymorphism Asp299Gly has evolved as a pro-
tective allele against malaria, explaining its high prevalence in
subSaharan Africa. However, the same allele could have been
disadvantageous after migration of modern humans into Eurasia,
putatively because of increased susceptibility to severe bacterial
infections. In contrast, the Asp299Gly allele, when present in
cosegregation with Thr399Ile to form the Asp299Gly/Thr399Ile
haplotype, shows selective neutrality. Polymorphisms in TLR4
exemplify how the interaction between our innate immune system
and the infectious pressures in particular environments may have
shaped the genetic variations and function of our immune system
during the out-of-Africa migration of modern humans.
cytokines  human migration  innate immunity  Toll-like receptor 4 
sepsis
During evolution, our genetic makeup has been profoundlyinfluenced, with important consequences for the predispo-
sition to health and disease. In the past decades, the interest in
the genetic and physiological mechanisms of predisposition to
disease has led to the identification of several genetic polymor-
phisms that have evolved in response to specific evolutionary
pressures. Among these, some of the best known are related to
the susceptibility to infectious diseases: the selection of hemo-
globin S, hemoglobin C, and thalassaemia  and  as protective
mechanisms against malaria (1–3), the polymorphisms in CCR5
providing protection against plague or HIV infection (4).
Toll-like receptors (TLR) have been discovered as the most
important class of pattern recognition receptors, involved in the
host defense against bacteria, viruses, fungi, and protozoa (5).
TLRs are evolutionarily conserved receptors for pathogenic
microorganisms, initially described in Drosophila (6) and with
homologues in plants and lower vertebrates (5). One of the
best-studied TLRs is TLR4, the key receptor for the LPS
component of Gram-negative bacteria and for structures of
mycobacteria, fungi, and malaria parasites (7–10).
Two nonsynonymous TLR4 polymorphisms have been de-
scribed, an A/G transition at SNP rs4986790 that causes an
Asp/Gly polymorphism at amino acid 299 and a C/T transition
at SNP rs4986791 that causes a Thr/Ile polymorphism at amino
acid 399. The derived states (G and T, or Gly and Ile, respec-
tively) have been shown to change the ligand-binding site of the
receptor (11). Both these two derived states reach substantial
frequencies and are found in cosegregation in Caucasian pop-
ulations (12–14). Some, but not all, studies have suggested a
correlation between these polymorphisms and susceptibility to
infectious diseases such as Gram-negative infections or dissem-
inated candidiasis (15–17). Despite a 98% cosegregation level of
these two derived alleles in Caucasian populations, this aspect
was not taken into account in susceptibility analyses: each
polymorphism was treated as an independent variable in these
studies (see review in ref. 13). In contrast to the situation in
Caucasians, one study inWest Africa identified a different TLR4
haplotype composed only of the Asp299Gly-derived allele, with
no individuals bearing the Thr399Ile-derived allele (18). These
differences suggest that human populations around the world
differ in the prevalence of TLR4 haplotypes, which in turn may
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reflect particular local infectious pressure and subsequent sus-
ceptibility to these infections.
In this study, we investigated whether the differences in the
TLR4 polymorphism haplotypes in various populations of the
three large continental masses, Africa, Eurasia, and America,
could have been the result of local evolutionary pressures by
infection during or after the out-of-Africa migration of modern
humans. We analyzed the prevalence of the TLR4 haplotypes
formed by these two SNPs in various populations from these
continents and compared the phenotype of the two most prev-
alent TLR4 haplotypes with the wild-type (ancestral) TLR4.
These results were used to get an insight into the evolutionary
pressure of infections on the TLR4 polymorphisms.
Results and Discussion
Distribution and Origin of the TLR4 Haplotypes Among the Popula-
tions. DNA from 2,491 individuals from 15 populations were
included for TLR4 polymorphism analysis. The location and
distribution of these populations were chosen to be representa-
tive of the original African populations before the migration and
the different migration routes toward Europe, Asia, and the New
World. As shown in Fig. 1, significant differences were found
between the existing prevalence of the two TLR4 polymorphisms
between the major continents. African populations show a high
prevalence of the Asp299Gly allele (rs4986790 G). Between 10%
and 18% of the individuals tested have one copy of this allele, of
which only 2% are present with Thr399Ile (rs4986791 T). The
Thr399Ile allele was always found in individuals with Asp299Gly.
Populations from Asia (Han Chinese, Indonesian, and Papuan)
and America (Trio Indians in Surinam) were practically missing
TLR4 polymorphisms, with single cases of the Asp299Gly allele
alone or the Thr399Ile allele alone in Indonesia. In contrast,
6–14% of Indo-European individuals were double heterozygotes
for the Asp299Gly and Thr399Ile alleles (allele frequency 3–7%,
respectively), a frequency that reaches 18% for Basques (allele
frequency 9%) [allele frequencies, supporting information (SI)
Table 3].
Because of the heterozygote state of most individuals bearing
the Asp299Gly and Thr399Ile alleles in European populations,
we analyzed whether these polymorphisms were in cosegregation
on the same allele or whether the polymorphisms laid on
different alleles. Several two-generation European families were
investigated for the presence of these alleles to confirm that both
polymorphisms were on the same haplotype and were therefore
inherited in cosegregation. In all situations with a parent double
heterozygote for Asp299Gly and Thr399Ile and a parent bearing
wild-type TLR4 alleles, all heterozygous children had both
Asp299Gly and Thr399Ile, confirming the cosegregated state of
both alleles (Fig. 2). Therefore, double-heterozygous
Asp299Gly/Thr399Ile individuals were assumed to contain one
haplotype with the two ancestral alleles and one haplotype with
the two variant alleles in further analysis. This haplotypic
composition is supported by the inferred phased haplotypes for
the reference HapMap populations (19).
Statistical analysis showed that all populations were in Hardy–
Weinberg equilibrium. In addition, haplotype similarity analysis
between the populations confirmed that the African, West-
Eurasian (European), and East-Eurasian (including the Amer-
ican) populations segregate into three major groups according to
their TLR4 haplotypes (Table 1). Interestingly, an Israeli pop-
ulation was the only one showing a mixed pattern of TLR4
haplotypes. This finding could have two possible explanations:
either this is a testimony of the current mosaic of the population
of Israel, encompassing emigration from many parts of the
world, or alternatively, this may represent a particular distribu-
tion of the TLR4 haplotypes in the Middle East. More Middle
Eastern populations should be studied for clarification of these
aspects.
The clustering pattern of the TLR4 haplotypes in the various
populations according to their geographical location suggests, on
the one hand, that the present pattern of TLR4 haplotypes may
be explained by the out-of-Africa migration routes of modern
humans (Fig. 1) and, on the other hand, that these differences
may have been shaped by local environmental conditions (e.g.,
infectious pressure). Archaeological and genetic evidence sug-
gests that anatomically modern humans originated 195,000
years ago in subSaharan Africa (16, 20, 21). Approximately
55,000–60,000 years ago, a first wave of migration traversed the
Bab-el-Mandab strait from the Horn of Africa to the Arabic
peninsula. From this West Asian source, humans migrated
toward Southeast Asia, reaching Australia by 50,000 years ago
(22), and toward Northern Eurasia (and subsequently to Amer-
ica from a Northeast Asian source) 40,000 years ago (ref. 23;
Fig. 1).
The presence of Asp299Gly and Thr399Ile in the African pop-
ulations, as well as in the Basque and Indo-European populations,
suggests these are mutations that arose in Africa60,000 years ago
and migrated toward Europe through theMiddle Eastern route. In
addition, the much higher prevalence of the Asp299Gly haplotype
compared with the Asp299Gly/Thr399Ile haplotype in Africa
(whereas Thr399Ile is in linkage with Asp299Gly allele; Fig. 1 and
SI Table 3), suggests the Asp299Gly mutation arose first, whereas
Fig. 1. World distribution of the TLR4 haplotypes in human populations.
Circles indicate allele frequency (red, Asp299Gly; yellow, Thr399Ile; and blue,
Asp299Gly/Thr399Ile). The Asp299Gly haplotype is concentrated in Africa, and
the Asp299Gly/Thr399Ile haplotype is concentrated in Europe. Arrows indicate
the main out-of-Africa migration routes of modern Homo sapiens, based on
refs. 19–21. Abbreviations used for the populations (and numbers): Ba,
Basque, Spain (107); Nl, The Netherlands (209); Ge, Germany (632); Ro, Roma-
nia (102); Gr, Greece (162); Is, Israel (85); Ch, Han Chinese, China (100); Tr,
Trio-Indians, Surinam (99); Do, Dogon tribe, Mali (241); Fu, Fulani tribe, Mali
(243); Ca, Cameroon (142); Ta, Tanzania (121); Su, Sudan (101); In, Indonesia
(98); and Pa, Papua New Guinea (49).
Fig. 2. Inheritance of the Asp299Gly/Thr399Ile heterozygote haplotype
within two different families. Asp299Gly and Thr399Ile polymorphisms coseg-
regate in the European populations.
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the Thr399Ile mutation must have appeared later a chromosome
bearing the Asp299Gly mutation.
Phenotypes of the Different TLR4 Haplotypes. The difference in the
frequency of the TLR4 haplotypes demonstrates there must have
been a shift in the population frequencies of the polymorphisms
during or after the migration. To answer which evolutionary or
genetic force could have caused the shift responsible for the
current distribution of TLR4 haplotypes in Europe and Asia,
which differ from that found in Africa, we assessed whether
TLR4 haplotypes result in a different functional activity of the
receptor. Therefore, we studied the functionality of the two most
common haplotypes, namely the ancestral 299–ancestral 399/
Asp299Gly–ancestral 399 haplotypes in one African (Dogon)
population and the ancestral 299–ancestral 399/Asp299Gly–
Thr399Ile haplotypes in one European (Dutch) population,
which both have a high prevalence of these haplotypes (Fig. 1 and
SI Table 3). Whole-blood samples from Dogon individuals were
exposed to increasing concentrations of bacterial LPS. Cells
from Asp299Gly heterozygous individuals (homozygous for the
ancestral state at 399) released significantly higher amounts of
the proinflammatory cytokine TNF- than those from donors
with a double-homozygous wild-type (ancestral state) genotype
TLR4 (Fig. 3A). No differences were observed in the production
of the antiinflammatory cytokine IL-10 (Fig. 3B). In contrast,
the presence of the double-heterozygous Asp299Gly/Thr399Ile
in cosegregation in the Dutch population did not modulate
cytokine production induced by LPS: no differences in TNF- or
IL-10 production were observed between individuals bearing the
double-heterozygous wild-type genotype and those heterozy-
gous for the Asp299Gly/Thr399Ile alleles (Fig. 3 C and D). Cells
harvested from one individual homozygous for the Asp299Gly/
Table 1. TLR4 allele differentiations between populations
Population (numbers) Tr Pa Ch In NL Ge Ba Gr Ro Is Su Ca Ta Do
Trio-Indians (99)
Papua (49) *
Han Chinese (100) * *
Indonesia (98) 0.120 0.704 0.123
The Netherlands (209) 0.001 0.003 0.001 0.001
Germany (632) 0.001 0.020 0.001 0.001 0.346
Basque (107) 0.001 0.001 0.001 0.001 0.361 0.095
Greece (162) 0.029 0.468 0.030 0.083 0.001 0.002 0.001
Romania (102) 0.001 0.002 0.001 0.001 0.403 0.111 0.547 0.012
Israel (85) 0.001 0.006 0.001 0.001 0.001 0.001 0.002 0.002 0.004
Sudan (101) 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.004
Cameroon (142) 0.001 0.006 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.004 0.394
Tanzania (121) 0.001 0.012 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.156 0.211 0.337
Dogon (241) 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.897 0.479 0.081
Fulani (243) 0.023 0.235 0.024 0.021 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.008 0.001 0.001
Allele distribution differences between each population were tested according to the Fisher exact test. These data show a clustering of the populations into
an African, West-Eurasian, and East-Eurasian group. Each asterisk indicates populations that could not be analyzed because only the wild-type allele was present.
Abbreviations are as in Fig. 1.
Fig. 3. Production of cytokines induced by LPS in individuals bearing the Asp299Gly or Asp299Gly/Thr399Ile haplotypes. Mean TNF- (A and B) and IL-10 (C and
D) concentrations are given as mean and SEM (nanograms per milliliter) from Asp299Gly heterozygotes (n  4) and wild-type individuals (n  32) with Dogon
ethnicity (A and C) and Asp299Gly/Thr399Ile heterozygotes (n  4) and wild-type individuals (n  8) from The Netherlands (B and D). Significant difference: *,
P  0.04; **, P  0.03 (Mann–Whitney U test).









Thr399Ile allele also displayed a normal production of pro- and
antiinflammatory cytokines. These data demonstrate that the
Asp299Gly allele is accompanied by a proinflammatory pheno-
type, whereas the Asp299Gly/Thr399Ile haplotype does not
functionally differ from wild-type TLR4. In addition, our data
represent an important argument suggesting caution in the
interpretation of overexpression studies of the different forms or
TLR4, which are known to be prone to artifacts due to unequal
efficiency of receptor expression. In this respect, overexpression
studies in cell lines have suggested that Asp299Gly and
Asp299Gly/Thr399Ile TLR4 expression may lead to a defective
function of TLR4 (11, 12). However, this assertion has been
refuted in case of the Asp299Gly/Thr399Ile TLR4 haplotypes by
many experimental and clinical studies (24–26), and our results
also do not confirm a decreased function of the Asp299Gly
haplotype.
Functional studies of the TLR4 gene neglected the TLR4
Asp299Gly allele in human primary cells; other studies to date
were performed in Caucasians bearing the cosegregated
Asp299Gly/Thr399Ile haplotype or used cell lines transfected
with the mutated TLR4. The proinflammatory phenotype of the
TLR4 Asp299Gly allele may represent the explanation of why
this haplotype disappeared from Eurasia: the strongly enhanced
TNF production may predispose for an increased mortality in
septic shock by contributing to the systemic inflammatory re-
sponse syndrome (27). In the only study that investigated the role
of all TLR4 haplotypes on the susceptibility to septic shock,
Lorenz et al. (16) showed that the presence of the Asp299Gly
alone, but not that of the Asp299Gly/Thr399Ile haplotype, is
associated with an increased mortality to septic shock. A strong
body of medical literature demonstrates the deleterious effects
of high cytokinemia during septic shock (28), and this most likely
explains the evolutionary disadvantage of a strong proinflam-
matory bias in individuals with a Asp299Gly allele (and homozy-
gous for the wild-type allele of the 399 polymorphism) who
migrated into Eurasia toward northern latitudes. Pandemic
infections of the past millennia such as plague (Yersinia pestis
infection), typhoid fever, and influenza (with its important
secondary bacterial infections) may also have been contributors
to this particular geographical distribution (29). A similar sce-
nario may have been behind the loss of the Asp299Gly allele in
Asia.
Evolutionary Neutral Phenotype of Asp299Gly/Thr399Ile Haplotype.
Although these data could explain the difference in frequency of
theAsp299Gly betweenAfrica andEurasia, they are not the reason
for the variable prevalence of the cosegregated Asp299Gly/
Thr399Ile haplotype in the different populations, ranging from 0%
in Asian populations, 1–2% in African populations, and 5% in
Dutch Indo-Europeans, to 9% in Basques. One clue may come
from the observation that cells from individuals with the
Asp299Gly/Thr399Ile haplotype have a response to LPS stimula-
tion that is indistinguishable from that of cells with wild-type TLR4
alleles (Fig. 3). This is supported by data from other in vitro (17, 25,
26) and ex vivo studies (24). Thus, although the presence of
Asp299Gly alone is accompanied by an increased function of the
receptor, the Asp299Gly/Thr-399/Ile haplotype results in an LPS/
TLR4 interaction similar to that present inwild-type individuals. To
strengthen these experimental data, we investigated the effect of
the Asp229Gly/Thr399Ile haplotype on the severity of sepsis. First,
no significant differences were observed in the prevalence of the
Asp299Gly/Thr399Ile haplotype between a healthy control popu-
lation (6%) and a cohort of patients with Gram-negative sepsis
(7%). Second, the severity and clinical parameters of sepsis were
similar in patients bearing two wild-type haplotypes or one wild-
type haplotype and one Asp299Gly/Thr399Ile haplotype (Table 2),
suggesting that the later TLR4 haplotype does not increase suscep-
tibility and mortality because of severe Gram-negative infections.
Thus, these clinical data also point to a neutral effect of the
Asp299Gly/Thr399Ile phenotype and suggest that the spread of this
cosegregated haplotype is the consequence not of infectious pres-
sure but more likely of functional neutrality and chance (genetic
drift and/or bottlenecks).
Another aspect concerning the phenotypic consequences of
the Asp299Gly/Thr399Ile TLR4 variant refers to noninfectious
diseases such as atherosclerosis (30) and nonallergic asthma (31),
in which some studies (albeit not all) proposed a beneficial effect
of the TLR4 polymorphisms. However, although these diseases
are important for the long-term quality of life of an individual,
they are very unlikely to have played any role in selection
processes, because of the age at which they affect the individual
and which is after the reproductive period.
In addition, to test whether the increased frequency of
Asp299Gly/Thr399Ile was due to some kind of positive selection
acting on this haplotype, we evaluated whether the extent of
haplotype homozygosity (EHH) (EHH test; see Materials and
Methods) was longer than expected under neutrality. After exten-
sive simulations using a neutral coalescent model with recombina-
tion (see Materials and Methods), we observed that, although the
EHH at the 3 end seems to be longer than expected under
neutrality (observed length until EHH  1  257,122 bp; 95%
expected upper limit, 242,319 bp), however, the 5 end shows a drop
in EHH already at 41,895 bp from the core, whereas the expected
95% is at least 350,000 bp. This reinforces the idea that neutrality
Table 2. Epidemiological and clinical data in 159 Indo-European patients with sepsis bearing




Number of patients 150 9 —
Age (mean  SD, years) 59.4  18.8 57.4  19.3 0.76
Male/female 112/38 8/1 0.58
APACHE II (mean  SD) 15.9  5.5 14.3  5.1 0.17
SOFA score (mean  SD) 7.87  3.32 7.33  3.00 0.65
Lymphocytes count (mean  SD/ml) 13.3  6.7 13.1  3.8 0.93
CRP (mg/liter, median IQR) 145.0 (669) 221.5 (260) 0.49
Septic shock, % 67 (44.7%) 4 (44.4%) 0.51
Mortality, % 45 (30.0%) 1 (11.1%) 0.51
To assess possible differences in the clinical outcome between the TLR4 wild-type and Asp299Gly/Thr399Ile
haplotypes, the Acute Physiology and Chronic Health Evaluation II (APACHE II) disease score, the Sepsis-Related
Organ Failure Assessment (SOFA) disease severity score, C-reactive protein (CRP), and the percentage of patients
with septic shock were measured. Mann–Whitney U test statistics showed no differences in the epidemiological
and clinical parameters between the two groups of patients.
16648  www.pnas.orgcgidoi10.1073pnas.0704828104 Ferwerda et al.
is a compatible hypothesis to explain the evolution of this haplotype
in Europeans.
Two Faces of Asp299Gly. Why is the Asp299Gly haplotype still
found in Africa? The increased mortality due to severe sepsis
(i.e., severe bacterial infection) could represent an important
evolutionary disadvantage in individuals bearing the Asp299Gly
allele (wild-type allele homozygotes for 399) who migrated into
Eurasia toward northern latitudes, whereas demography and
genetic drift can be sufficient to explain the frequencies of
Asp299Gly/Thr399Ile. This leaves the question why there is a
high prevalence of Asp299Gly allele (associated with a wild-type
allele at ‘‘399’’) in subSaharan Africa. As a putative evolutionary
pressure in subSaharan Africa, malaria immediately comes to
mind. Indeed, it has been demonstrated that, although the
Asp299Gly allele increases susceptibility to malaria in a Ghanese
population, mortality was lower in individuals with Asp299Gly
allele compared with ‘‘299’’ wild-type TLR4 patients (9). We
have been able to confirm and extend this observation in a pilot
study in a malaria hyperendemic region of Cameroon. In chil-
dren with malaria, the presence of the Asp299Gly haplotype was
associated with higher parasitemia (80% higher compared with
the TLR4‘‘299’’ wild type) yet lower prevalence of cerebral
malaria (12% compared with 24% in the TLR4‘‘299’’ wild-type
group) (B.F., unpublished results). These findings strongly sug-
gest that the higher prevalence of haplotype Asp299Gly/wild-
type ‘‘399’’ in subSaharan Africa is due to protection against
mortality from malaria. Thus, the TLR4 amino acid site 299
(more precisely, SNP rs4986790) should be added to the list of
gene polymorphisms selected by malaria, next to sickle cell
disease, thalassaemias, and TNF polymorphisms (1, 2, 32).
In summary, we present evidence that the TLR4‘‘299’’-‘‘399’’
(rs4986790–rs4986791) haplotypes are geographically clustered.
Functional data in individuals bearing the haplotype composed
of the Asp299Gly allele associated to the wild-type ‘‘399’’ allele
demonstrate a proinflammatory profile in line with an increased
susceptibility to septic shock in patients bearing this haplotype
(16). In contrast, this allele seems to protect against mortality in
severe malaria (9), although the mechanism of protection is not
yet understood. In Africa, where malaria exercises a strongly
selective pressure, the beneficial effect of Asp299Gly in malaria
seems to override the negative effect in sepsis. During the
migration of humans into Eurasia, where malaria is less preva-
lent, the Asp299Gly allele was eliminated because of increased
mortality in severe Gram-negative bacterial infections. The
absence of the TLR4 polymorphisms in the Trio Indians from
South America is a testimony that these evolutionary pressures
have already eliminated the Asp299Gly/wild-type ‘‘399’’ haplo-
type in the population that migrated over the Behring strait to
the New World 15,000 years ago. In contrast, the variable
prevalence of the Asp299Gly/Thr399Ile haplotype in the Eur-
asian populations is most likely the result of genetic drift.
This study explains the geographic distribution of the TLR4
haplotypes in populations according to susceptibility to infection
and provides an understanding of how our innate immune system
has been molded by infectious pressures.
Materials and Methods
DNA Samples and Asp299Gly and Thr399Ile Screening.DNA samples
from theHan people came fromCorriell (Camden, NY) (catalog
no. HD1000CHI). All other DNA was extracted from whole
blood by using the isolation kit Puregene (Gentra Sytems,
Minneapolis, MN). PCR conditions, concentrations, and deter-
minations of the Asp299Gly and Thr399Ile polymorphisms were
preformed as described by Van Der Graaf et al. (17).
Cytokine Stimulation Assays. Venous whole blood was collected
into 2-ml heparin tubes (BD, Plymouth, U.K.). Blood from
healthy individuals of Dogon ethnicity was diluted to a final
concentration of 1:5 in RPMI medium 1640 (containing 1%
glutamine, 1% pyruvate, and 1% gentamicin) and stimulated
with control medium or highly purified LPS at various concen-
trations (0.1, 1, and 10 g/l). After 24 h at 37°C, supernatants
were collected and stored at80°C until cytokine measurements
were done.
In the Dutch population, venous blood was collected in EDTA
tubes, and peripheral blood mononuclear cells were isolated by
density centrifugation on Ficoll–Hypaque (Amersham Bio-
sciences, Diegem, Belgium). Peripheral blood mononuclear cells
resuspended in RPMI medium 1640 were plated into 96-well cell
culture plates at a final density of 5 106 cells/ml and stimulated
for 24 h at 37°C with RPMI medium 1640 or LPS (0.1, 1, and 10
g/l). After 24 h, supernatants were collected and stored at
80°C until cytokine measurements were done.
Cytokine Measurements. IL-10 cytokine concentrations were mea-
sured by sandwich ELISA (Sanquin, Amsterdam, The Nether-
lands). TNF- production was measured by a specific ELISA, as
described (33).
Sepsis Patients. Blood was sampled from 162 patients with
ventilator-associated pneumonia and sepsis. Diagnosis was made
by published criteria (34). Patients were followed up for 28 days.
Disease severity was assessed by Acute Physiology and Chronic
Health Evaluation II (APACHE II) and Sepsis-Related Organ
Failure Assessment (SOFA) scores on the first day of diagnosis,
and mortality was given at the end of the observation period.
C-reactive protein was estimated in serum by a nephelometric
assay (Behring, Berlin, Germany).
Statistics. The distributions between the TLR4 alleles in the
different populations and theHardy–Weinberg equilibriumwere
preformed with the GENEPOP program (35). The differentia-
tion analysis is based on the unbiased estimation of the P value
of a log-likelihood- (G) based exact test, which is based on the
same principles as Fisher’s exact test.
Cytokine and sepsis statistics were performed by using the
SPSS program (Rel. 14.0.2, 2006; SPSS, Chicago, IL), and
differences were tested by the Mann–Whitney U test. P  0.05
was considered to represent a statistically significant difference.
As a neutrality test, we applied the EHH test (36) to the phased
genotypic information available from HapMap Data Rel. 21a/
phaseII Jan 07, on National Center for Biotechnology Information
NB35 assembly, dbSNP b125. We used as the core haplotype that
formed by allele G of rs4986790 and allele T of rs4986791 within
TLR4 (which corresponds to haplotype Asp299Gly/Thr399Ile). We
analyzed the extent to which the EHH for this core haplotype was
1 in the HapMap Caucasian population in a genomic region that
extended 350 kb in both directions from the core. To test whether
the distance observed was longer than expected under neutrality,
we ran coalescent simulations that took into account the hetero-
geneity in recombination rates across these regions (obtained from
theHapMap link) bymeans ofmsHOT (37).We used demographic
parameters reflecting the out-of-Africa model of human evolution
by slightly modifying Schaffner et al.’s model (38). Simulations were
run for both the 350 kb downstream from the core and the 350 kb
upstream from the core. The number of SNPs was adjusted to that
observed in the HapMap sample for that region. We added three
filters to the neutral simulations: (i) We considered only those
simulations that resulted in a number of different haplotypes equal
to that observed in the HapMap sample (as determined by the core
SNPs rs4986790 and rs4986791); in the simulations, the first two
SNPs were considered the core set. (ii) In addition, one of the
simulated core haplotypes had to show a similar frequency to that
core haplotype under examination [obtained from the HapMap
Caucasian SNP information and defined by core SNPs (allele G of









rs4986790 and allele T of rs4986791)]. (iii) The ancestral/derived
states of the core SNPs in this preselected simulated haplotype also
had to be identical to the ancestral/derived states of the core SNPs
at the core haplotype under examination. By comparison with the
orthologous genome regions of the chimpanzee and Rhesus ma-
caque, both G and T were defined as ‘‘derived.’’ Simulations
satisfying these conditions were kept, but only the information on
the core haplotype was used for the EHH analysis. Finally, the
extent from the core SNPs for which EHH was 1 was recorded for
the observed HapMap data, and this was tested against the distri-
bution obtained from the filtered simulations.
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